🔍

ORTIN GLOBAL LIMITED (ORTINGLOBE)

₹14.34 +0.28% last close, 16 Oct

📊 NSE: ORTINGLOBE 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📢 Latest filing: 30 Sep 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, ORTIN GLOBAL's revenue was ₹0.0 Cr (-80.0% year on year, -94.7% on the previous quarter), and net profit ₹-0.3 Cr (a bigger loss than a year earlier); the operating margin was -2089.4%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹0.0	-80.0%	-94.7%
Operating profit	₹-0.3	loss widened	loss widened
Net profit	₹-0.3	loss widened	loss widened
EPS (₹)	-0.42	loss widened	loss widened
Operating margin	-2089.4%	—	—

Full quarterly financials → Results calendar →

ORTINGLOBE delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 91.5% of the ORTINGLOBE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 77.59%. That is higher than usual for this stock. Turnover was only ₹1 lakh, so a handful of trades can move this figure. It closed at a price band (circuit) on 4 sessions in about the last 20.

91.5%Delivery, 16 Oct

77.59%Own 20-session average

0.6×Volume vs its average

₹14.34NSE close · +0.28%

Delivery in the last 5 sessions: 99.5% · 99.6% · 53.6% · 66.5% · 91.5%

Delivery across the market →Circuit stocks →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Ortin Global Concludes 39th AGM; Re-designates Key Management and Approves Directorships

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 30 Sep 2026, 09:33 PM

Ortin Global Limited concluded its 39th Annual General Meeting on September 30, 2026, attended by 39 members. Key resolutions included adopting audited financial statements for FY 2025-26, re-designating Murali Krishna Murthy Sanka from Managing Director to Non-Executive Director, and re-designating Prashant Prakash Sawant from Whole-Time Director to Managing Director. Additionally, the appointment of Parveen Satija as Whole-Time Director was tabled for shareholder approval, with final scrutinizer results to follow.

Held 39th Annual General Meeting on September 30, 2026, between 5:00 p.m. and 5:25 p.m. IST
Total of 39 members attended the AGM via video conference
Approval tabled for redesignating Prashant Prakash Sawant from Whole-Time Director to Managing Director
Murali Krishna Murthy Sanka redesignated from Managing Director to Non-Executive Director
E-voting remained active for 15 minutes post-meeting conclusion; final Scrutinizer's Report awaited

💡 Track the upcoming disclosure of voting results and Scrutinizer's Report to confirm the formal passage of the leadership transitions.

Ortin Global Whole-Time Director Prakruti Prashant Sawant Resigns Effective Sept 7, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 08 Sep 2026, 08:42 PM

Ortin Global Limited has informed the exchanges regarding the resignation of Prakruti Prashant Sawant (DIN: 11162997) from the position of Whole-time Director. The resignation is effective from September 7, 2026, citing professional commitments. The director confirmed that there are no other material reasons for the departure. The company continues to face financial stress, with a low promoter holding of 1.23% and negative other equity of ₹6.83 Cr.

Whole-time Director Prakruti Prashant Sawant resigned effective 07.09.2026
Director DIN cited as 11162997
Resignation attributed to professional commitments with no other material reasons cited
Company trades with an extremely low promoter holding of 1.23%

💡 Track subsequent filings for appointment of replacement executive management and monitoring half-yearly operational results given existing negative equity levels.

Ortin Global Calls 39th AGM on Sept 30, Proposes Leadership Reshuffle Amid Going-Concern Caveat

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 08 Sep 2026, 06:00 PM

Ortin Global Limited has issued the notice for its 39th Annual General Meeting scheduled for September 30, 2026, with a cut-off date of September 23, 2026. The agenda includes re-designating former MD Murali Krishna Murthy Sanka to Non-Executive Director at Rs 50,000 per month, appointing Prashant Prakash Sawant as MD at Nil remuneration, and appointing Parveen Satija as Whole-time Director. Notes in the annual report highlight severe financial strain, noting that net worth is eroded by over 50% with cash losses, leading to accounts being prepared on a going concern basis alongside unaudited cash of Rs 35.50 Lakhs.

39th Annual General Meeting scheduled for September 30, 2026 via VC/OAVM, with cut-off date of September 23, 2026
Prashant Prakash Sawant appointed Managing Director for 3 years w.e.f. September 7, 2026 at Nil remuneration
Murali Krishna Murthy Sanka moved to Non-Executive Director at a monthly remuneration of Rs. 50,000
Auditor note reports net worth erosion exceeds 50% along with cash losses, prepared on going concern basis
Cash balance stood at Rs. 35.50 Lakhs as of March 31, 2026, which lacked physical verification by the auditor

💡 Track shareholder voting outcomes post-September 30, 2026, and watch upcoming quarterly results to see if the new leadership can reverse persistent operating losses.

Ortin Global Overhauls Leadership: Appoints New MD and Whole-Time Director

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 07 Sep 2026, 11:08 PM

Ortin Global Limited has reconstituted its executive management effective September 7, 2026, subject to shareholder approval. Former Whole-time Director Prashanth Prakash Sawant has been redesignated as Managing Director for a 3-year term ending September 6, 2029, replacing Murali Krishna Murthy Sanka, who transitions to Non-Executive Director. Concurrently, Prakruti Prashant Sawant resigned from the board, and Parveen Satija was appointed as Additional and Whole-time Director for a 2-year tenure ending September 6, 2028. The company's 39th Annual General Meeting is scheduled for September 30, 2026.

Prashanth Prakash Sawant redesignated as Managing Director for a 3-year term (07.09.2026 to 06.09.2029)
Parveen Satija appointed as Additional and Whole-time Director for 2 years (holding 1,00,526 equity shares)
Outgoing MD Murali Krishna Murthy Sanka (holds 17,844 equity shares) transitions to Non-Executive Director
Prakruti Prashant Sawant resigned as Whole-time Director effective close of business on 07.09.2026
39th Annual General Meeting convened for 30th September 2026 via VC/OAVM

💡 Track voting outcomes at the upcoming AGM on September 30, 2026, and watch for operational turnaround strategies under the new Managing Director given persistent operating losses.

Ortin Global Overhauls Leadership: Appoints New MD and Whole-time Director, Sets AGM for Sept 30

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 07 Sep 2026, 11:06 PM

Ortin Global Limited has approved significant leadership restructuring in its board meeting held on September 7, 2026. Prakash Prashanth Sawant has been redesignated from Whole-time Director to Managing Director for a 3-year term ending September 6, 2029, while former MD Murali Krishna Murthy Sanka transitions to Non-Executive Director. Additionally, Prakruti Prashant Sawant resigned as Whole-time Director, and Parveen Satija was appointed as Additional and Whole-time Director for a 2-year term. The company has convened its 39th Annual General Meeting for September 30, 2026, to seek shareholder approvals.

Prakash Prashanth Sawant appointed Managing Director for a 3-year term from September 7, 2026 to September 6, 2029
Murali Krishna Murthy Sanka moved from Managing Director to Non-Executive Director effective September 7, 2026
Parveen Satija appointed as Additional and Whole-time Director for 2 years (holds 1,00,526 equity shares)
Prakruti Prashant Sawant resigned from the post of Whole-time Director effective September 7, 2026
39th Annual General Meeting scheduled for September 30, 2026 at 5:00 p.m. via video conference

💡 Track shareholder voting results from the upcoming AGM on September 30, 2026, regarding these leadership appointments and monitor any upcoming strategic turnaround plans.

Q1 FY27 Net Loss Widens to ₹33.79 Lakh as Total Income Drops 80% YoY to ₹1.60 Lakh

🔴 NEGATIVE ⭐ 5/10

EARNINGS 📅 14 Aug 2026, 07:55 PM

Ortin Global reported a net loss of ₹33.79 lakh for the quarter ended June 30, 2026, widening from a loss of ₹17.54 lakh in Q1 FY26. Net sales from operations declined to ₹1.16 lakh compared to ₹3.98 lakh in the year-ago period, pulling total income down 80.2% YoY to ₹1.60 lakh. Total expenses increased 43.8% YoY to ₹35.06 lakh, largely driven by other expenditures of ₹29.97 lakh. EPS worsened to -₹0.42 per share from -₹0.22 in Q1 FY26.

Total Income dropped 80.2% YoY to ₹1.60 lakh compared to ₹8.09 lakh in Q1 FY26
Net loss widened to ₹33.79 lakh versus ₹17.54 lakh in Q1 FY26 and ₹0.93 lakh in Q4 FY26
Net sales from operations remained minimal at ₹1.16 lakh vs ₹3.98 lakh in Q1 FY26
Total expenses stood at ₹35.06 lakh, led by other expenditure of ₹29.97 lakh and employee expenses of ₹4.02 lakh

💡 Track whether management outlines any viable business revival strategy or capital restructuring, as operational scale remains negligible relative to overhead costs.

Ortin Global Submits Quarterly Compliance Certificate for June 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Jul 2026, 04:23 PM

Ortin Global Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018. The certificate, issued by the company's Registrar and Share Transfer Agent (RTA), KFin Technologies Limited, covers the quarter ended June 30, 2026. It confirms that all necessary details regarding the dematerialization and rematerialization of securities have been reported to the stock exchanges (BSE and NSE). This is a standard procedural filing required for all listed entities in India.

Compliance certificate issued for the quarter ended June 30, 2026
Certificate provided by RTA KFin Technologies Limited dated July 01, 2026
Confirmation of reporting dematerialization/rematerialization activities to BSE and NSE
Filing submitted to exchanges on July 11, 2026

💡 No action is required as this is a routine administrative filing. Investors should monitor the company's upcoming quarterly financial results for operational performance updates.

Ortin Global Clarifies Single Segment Operations for FY26 Financial Results

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 09 Jul 2026, 05:43 PM

Ortin Global Limited (formerly Ortin Laboratories) responded to an NSE query dated June 27, 2026, regarding the absence of segment-wise reporting in its FY26 results. The company clarified that segment reporting is not applicable as it operates exclusively in the 'Drugs and Medicines' segment. This administrative clarification follows a previous response on July 6, 2026. The company's financial position remains weak with a net worth of only ₹1 Cr and a negative ROCE of 32.1%.

Responded to NSE query dated June 27, 2026, regarding Regulation 33 compliance
Confirmed operations are limited to 1 segment: Drugs and Medicines
Clarification pertains to the financial results for the quarter and year ended March 31, 2026
Company maintains a very low promoter holding of 1.23% as of March 2026

💡 Focus on the company's upcoming quarterly results to see if the strategic rebranding to 'Ortin Global' translates into revenue growth, given the current negative ROCE of 32.1%.

Ortin Global Limited to Close Trading Window from July 1, 2026, for Q1 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Jun 2026, 05:46 PM

Ortin Global Limited has announced the closure of its trading window starting July 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is mandatory ahead of the board meeting to consider and approve the unaudited financial results for the quarter ending June 30, 2026. The trading window will remain closed for all designated persons and their relatives until 48 hours after the results are declared. This is a standard regulatory procedure for listed companies in India.

Trading window closure effective from July 1, 2026.
Closure pertains to the approval of unaudited financial results for the quarter ending June 30, 2026.
Window to reopen 48 hours after the official announcement of financial results.
Restriction applies to all designated persons, immediate relatives, and connected persons.

💡 No action is required as this is a routine regulatory filing. Investors should monitor for the future announcement of the board meeting date to review the company's Q1 performance.

Ortin Global Promoters Declare Zero Share Pledging for FY 2025-26

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 15 Jun 2026, 09:54 AM

S. Murali Krishna Murthy, representing the promoter group and Persons Acting in Concert (PAC) of Ortin Global Limited, has submitted the annual disclosure under SEBI Takeover Regulations. As of March 31, 2026, the promoter group collectively holds 1,00,300 equity shares in the company. The disclosure confirms that no shares were encumbered or pledged, either directly or indirectly, during the financial year 2025-26. This filing is a routine but essential compliance requirement to ensure transparency regarding promoter shareholding stability.

Promoters and PAC collectively hold 1,00,300 equity shares as of March 31, 2026.
Declaration confirms zero encumbrance or pledging of shares during the financial year 2025-26.
Compliance submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Disclosure has been filed with BSE, NSE, and the company's Audit Committee.

💡 Investors can take comfort in the fact that promoters have not pledged any shares, which indicates a lack of debt-related pressure on the promoter holding. No immediate action is required as this is a standard annual regulatory filing.

Ortin Global Promoters Disclose 1,00,300 Shares Held with No New Encumbrances in FY26

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 12 Jun 2026, 10:49 AM

S. Murali Krishna Murthy, representing the promoter group and Persons Acting in Concert (PAC) of Ortin Global Limited, has submitted the annual disclosure under SEBI (SAST) Regulations for the financial year ended March 31, 2026. The promoter group collectively holds 1,00,300 equity shares in the company. The filing explicitly states that no new encumbrances or pledges were created on these shares, directly or indirectly, during the reported financial year. This is a standard compliance procedure to ensure transparency regarding promoter shareholding and debt obligations.

Promoters and PAC hold a total of 1,00,300 equity shares as of March 31, 2026.
Declaration confirms zero new encumbrances or pledges were made during the 2025-26 financial year.
Submission complies with Regulation 31(4) and 31(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The disclosure was formally submitted to BSE, NSE, and the company's Audit Committee.

💡 Investors should view this as a routine regulatory filing that confirms the stability of promoter holdings without new debt-related pledges. No immediate portfolio action is required based on this disclosure alone.

Ortin Global IDC Recommends Open Offer by Parveen Satija at ₹14.65 Per Share

🟡 NEUTRAL ⭐ 8/10

M&A 📅 05 Jun 2026, 11:41 AM

The Committee of Independent Directors (IDC) of Ortin Global Limited has officially recommended the open offer made by Mr. Parveen Satija. The offer involves the acquisition of up to 21,14,162 equity shares, representing 26% of the company's fully paid-up equity capital. The IDC has deemed the offer price of ₹14.65 per share as fair and reasonable based on SEBI (SAST) Regulations. The offer is being managed by Rarever Financial Advisors Private Limited.

Open offer for 21,14,162 equity shares representing 26% of the total voting capital.
Offer price fixed at ₹14.65 per equity share, to be paid in cash.
Committee of Independent Directors (IDC) unanimously concluded the offer price is justified and fair.
The acquisition is being made by Mr. Parveen Satija (Acquirer) in compliance with SEBI Takeover Regulations.
No complaints have been received from shareholders regarding the valuation or process as of the report date.

💡 Shareholders should compare the current market price of Ortin Global with the offer price of ₹14.65. If the market price is higher than the offer price, tendering shares in the open offer may not be financially advantageous.

Ortin Global Approves FY26 Audited Financial Results with Unmodified Audit Opinion

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 30 May 2026, 07:52 PM

Ortin Global Limited (formerly Ortin Laboratories) has approved its audited financial results for the quarter and full year ended March 31, 2026. The company's statutory auditors, M/s. Mathesh & Ramana, issued an unmodified/unqualified opinion, confirming the reliability of the financial statements. The board meeting concluded at 7:30 PM on May 30, 2026, at the company's Hyderabad headquarters. While the specific profit and loss figures were not detailed in the cover letter, the clean audit report is a positive sign of regulatory compliance.

Board approved audited financial results for the quarter and year ended March 31, 2026.
Statutory auditors issued an unmodified/unqualified audit opinion for the full fiscal year.
Declaration submitted in compliance with Regulation 33(3)(d) of SEBI (LODR) Regulations.
The board meeting was conducted at the Hyderabad registered office and concluded at 07:30 PM.

💡 Investors should examine the full financial tables once available to evaluate year-on-year growth in revenue and margins. The clean audit report suggests no immediate red flags regarding accounting practices.

Ortin Global Limited Confirms Non-Applicability of Large Corporate Framework for FY 2026-27

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 06 May 2026, 06:06 PM

Ortin Global Limited has informed the exchanges that it does not qualify as a 'Large Corporate' under the SEBI circular dated October 19, 2023. While the company's equity shares are listed on BSE and NSE, it does not meet the other two criteria: outstanding long-term borrowings of ₹1,000 crore or more and a credit rating of 'AA' or above. This disclosure is a routine annual compliance requirement for the financial year 2026-2027. Consequently, the specific borrowing requirements applicable to Large Corporates do not apply to the company.

Company does not have outstanding long-term borrowings of ₹1,000 crore or more as of the last day of the preceding FY.
Company does not possess a credit rating of 'AA' or above for unsupported bank borrowings.
Compliance filed as per SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172.
The Large Corporate framework is officially not applicable for the financial year 2026-2027.

💡 This is a routine regulatory filing with no impact on business fundamentals; investors should continue to monitor the company's core financial performance.

Ortin Global Limited Confirms Non-Large Corporate Status for FY 2025-26

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 30 Apr 2026, 07:47 PM

Ortin Global Limited has submitted its annual disclosure to the exchanges, clarifying its status regarding SEBI's Large Corporate framework. The company confirmed it does not meet the specific criteria for a Large Corporate for the financial year 2025-26. Therefore, it is not required to raise 25% of its incremental borrowings through debt securities. The filing indicates zero debt security borrowings and no applicable penalties for the current or previous block periods.

Ortin Global Limited confirms it does not fall under the 'Large Corporate' category for FY 2025-26.
Actual borrowing through debt securities for the financial year 2025-26 was reported as Nil.
The company is exempt from the mandatory 25% borrowing requirement through debt securities.
No penalties are applicable for the 2-year block period ending FY 2025-26.

💡 This is a routine regulatory disclosure confirming the company's classification and has no impact on stock valuation. Investors should maintain their current positions and wait for operational updates.

View All ORTINGLOBE Announcements on Live Market Tracking →

💰 Financial Performance

Profitability Margins

Net loss for the half-year ended September 30, 2025, was INR 67.79 Lakhs, an increase of 17.81% compared to the INR 57.54 Lakhs loss in the previous year's corresponding period. However, the annual loss narrowed by 89.47% from INR 804.10 Lakhs in FY24 to INR 84.64 Lakhs in FY25.

EBITDA Margin

Operating profit before working capital changes was negative INR 70.49 Lakhs for the half-year ended September 30, 2025, indicating that core operations are currently not generating positive cash flow.

Credit Rating & Borrowing

Non-current borrowings increased by 272% to INR 93.00 Lakhs as of September 30, 2025, from INR 25.00 Lakhs as of March 31, 2025. Finance costs for the half-year were INR 0.15 Lakhs.

⚙️ Operational Drivers

Manufacturing Efficiency

Operating profit before working capital changes was negative INR 70.49 Lakhs, indicating that current production levels or pricing are insufficient to cover operating costs.

📈 Strategic Growth

Growth Strategy

The company is undergoing a strategic rebranding to 'Ortin Global Limited' to potentially expand its market reach. The Audit Committee is also mandated to review the rationale and cost-benefits of any mergers or demergers to drive future growth.

Products & Services

Pharmaceutical formulations and laboratory services (formerly Ortin Laboratories Limited).

Market Expansion

The name change to Ortin Global Limited suggests a plan to expand into international markets, though specific regions and timelines are not disclosed.

🌍 External Factors

Industry Trends

The pharmaceutical industry is seeing a shift towards global integration. Ortin is positioning itself through a name change to 'Global' to align with these trends, despite current financial headwinds.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to pharmaceutical manufacturing standards and SEBI/Companies Act regulations. Compliance is essential to avoid legal penalties that could strain the company's limited equity of INR 1.30 Cr.

⚠️ Risk Analysis

Key Uncertainties

The primary risk is the continued erosion of equity, with 'Other Equity' standing at negative INR 6.83 Cr, and the ability to service the 272% increase in borrowings.